GPR39 is a GPCR which can interact with Zn and modulate the colonocytes' survival. The clinical significance of GPR39 in colon cancer has never been reported. Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues The clinical significance of GPR39 was evaluated by analyzing the correlations with clinicopathological The prognostic significance of GPR39 was estimated with univariate and multivariate analyses.

Selenomethionine Promotes Milk Protein and Fat Synthesis and Proliferation of Mammary Epithelial Cells through the GPR37

Efferocytes release extracellular vesicles to resolve inflammation and tissue injury via prosaposin-GPR37

We detected the expression of GPR37 in NSCLC tissues and cell lines. The study explored the influence of GPR37 on tumor cell proliferation. Furthermore, we examined the effects of GPR37 on tumor cell apoptosis and invasion. Most importantly, we investigated whether GPR37 affects cisplatin-induced drug resistance in NSCLC. Knockdown of GPR37 significantly inhibits the occurrence and development of NSCLC.

Efferocytes release extracellular vesicles to resolve inflammation and tissue injury via prosaposin-GPR37 We report that efferocyte-derived EVs express prosaposin, which binds to macrophage GPR37 to increase Neutralization and knockdown of prosaposin or blocking GRP37 abrogates the pro-resolution effects of

contributions to understanding the signaling, regulation and in vivo actions of the neuroprotective receptors GPR37 & GPR37L1 as well as the adhesion GPCRs BAI1, BAI2, and GPR56.